Lauranne A. A. P. Derikx

Lauranne A. A. P. Derikx

Auto-generated profile, based on publicly available information

Lauranne A. A. P. Derikx

Edinburgh IBD Unit Western General Hospital Edinburgh UK

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2016 in Best Practice & Research Clinical Gastroenterology
Verified
Journal Article
Closed access
LDLauranne A.A.P. Derikx
Lauranne A.A.P. Derikx
LDLevinus A. Dieleman
Levinus A. Dieleman
FHFrank Hoentjen
Frank Hoentjen

30 June 2017 in Digestive Diseases and Sciences
Verified
Journal Article
Open access
PDF file
LSLisa J. T. Smits
Lisa J. T. Smits
AGAnna Grelack
Anna Grelack
LDLauranne A. A. P. Derikx
Lauranne A. A. P. Derikx
DJDirk J. de Jong
Dirk J. de Jong
AEAura A. J. van Esch
Aura A. J. van Esch
FHFrank Hoentjen
Frank Hoentjen
Purpose Orbital wall reconstruction remains a challenge in reconstructive CMF surgery due to the delicate anatomical structures and their potential functional impairment due to inefficient treatment. The use of biomaterials in reconstructive surgery has revolutionised the therapy in this area. Ultra-high molecular weight polyethylene (UHMWPE) has shown promising results due to its biocompatibility, mechanical properties, and versatility. This paper presents the first clinical study of the use of UHMWPE in orbital fracture reconstruction. Methods In a multicentre prospective study consisting of 50 patients undergoing orbital floor reconstruction, UHMWPE implants were used to reconstruct the orbital volume after fracture. 46 Patients underwent preoperative and postoperative 3D radiography and orbital volume segmentation. Results A significant postoperative volume reduction of the affected orbits was observed in the entire cohort (p < 0.001) with a significant alignment to the healthy contralateral orbits. There were no implant-related complications. Conclusion Orbital wall reconstruction with UHMWPE (marPOR) implants is a reliable method to restore adequate orbital volume for functional and aesthetic recovery in trauma patients.

20 October 2020 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
LDLauranne A A P Derikx
Lauranne A A P Derikx
MLMarten A Lantinga
Marten A Lantinga
DJDirk J de Jong
Dirk J de Jong
WDWillemijn A van Dop
Willemijn A van Dop
RCRob H Creemers
Rob H Creemers
FHFrank Hoentjen
Frank Hoentjen
Background and Aims: The COVID-19 risk and disease course in inflammatory bowel disease [IBD] patients remains uncertain. Therefore, we aimed to assess the clinical presentation, disease course, and outcomes of COVID-19 in IBD patients. Second, we determined COVID-19 incidences in IBD patients and compared this with the general population. Methods: We conducted a multicentre, nationwide IBD cohort study in The Netherlands and identified patients with COVID-19. First, we assessed the COVID-19 disease course and outcomes. Second, we compared COVID-19 incidences between our IBD study cohort and the general Dutch population. Results: We established an IBD cohort of 34 763 patients. COVID-19 was diagnosed in 100/34 763 patients [0.29%]; 20/100 of these patients [20%] had severe COVID-19 defined as admission to the intensive care unit, mechanical ventilation, and/or death. Hospitalisation occurred in 59/100 [59.0%] patients and 13/100 [13.0%] died. All patients who died had comorbidities and all but one were ≥65 years old. In line, we identified ≥1 comorbidity as an independent risk factor for hospitalisation (odds ratio [OR] 4.20, 95% confidence interval [CI] 1.58–11.17,; p = 0.004). Incidences of COVID-19 between the IBD study cohort and the general population were comparable (287.6 [95% CI 236.6–349.7] versus 333.0 [95% CI 329.3–336.7] per 100000 patients, respectively; p = 0.15). Conclusions: Of 100 cases with IBD and COVID-19, 20% developed severe COVID-19, 59% were hospitalised and 13% died. A comparable COVID-19 risk was found between the IBD cohort [100/34 763 = 0.29%] and the general Dutch population. The presence of ≥1 comorbidities was an independent risk factor for hospitalisation due to COVID-19.

2 September 2021 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
PDF file
NCNeil Chanchlani
Neil Chanchlani
SLSimeng Lin
Simeng Lin
DCDesmond Chee
Desmond Chee
BHBenjamin Hamilton
Benjamin Hamilton
RNRachel Nice
Rachel Nice
TATariq Ahmad
Tariq Ahmad
Infliximab attenuates serological responses to SARS-CoV-2 infection. Whether this is a class effect, or if anti-tumour necrosis factor [anti-TNF] level influences serological responses, remains unknown. Seroprevalence and the magnitude of SARS-CoV-2 nucleocapsid antibody responses were measured in surplus serum from 11 422 (53.3% [6084] male; median age 36.8 years) patients with immune-mediated inflammatory diseases, stored at six therapeutic drug monitoring laboratories between January 29 and September 30, 2020. Data were linked to nationally held SARS-CoV-2 PCR results to July 11, 2021. Rates of PCR-confirmed SARS-CoV-2 infection were similar across treatment groups. Seroprevalence rates were lower in infliximab- and adalimumab- than vedolizumab-treated patients (infliximab: 3.0% [178/5893], adalimumab: 3.0% [152/5074], vedolizumab: 6.7% [25/375], p = 0.003). The magnitude of SARS-CoV-2 reactivity was similar in infliximab- vs adalimumab-treated patients (median 4.30 cut-off index [COI] [1.94–9.96] vs 5.02 [2.18–18.70], p = 0.164), but higher in vedolizumab-treated patients (median 21.60 COI [4.39–68.10, p < 0.004). Compared to patients with detectable infliximab and adalimumab drug levels, patients with undetectable drug levels [<0.8 mg/L] were more likely to be seropositive for SARS-CoV-2 antibodies. One-third of patients who had PCR testing prior to antibody testing failed to seroconvert, all were treated with anti-TNF. Subsequent positive PCR-confirmed SARS-CoV-2 was seen in 7.9% [12/152] of patients after a median time of 183.5 days [129.8–235.3], without differences between drugs. Anti-TNF treatment is associated with lower SARS-CoV-2 nucleocapsid seroprevalence and antibody reactivity when compared to vedolizumab-treated patients. Higher seropositivity rates in patients with undetectable anti-TNF levels support a causal relationship, although confounding factors, such as combination therapy with a immunomodulator, may have influenced the results.

5 June 2021 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
PDF file
LDLauranne A A P Derikx
Lauranne A A P Derikx
HDHeather W Dolby
Heather W Dolby
NPNikolas Plevris
Nikolas Plevris
LLLaura Alexandra Lucaciu
Laura Alexandra Lucaciu
CRCaitlin S Rees
Caitlin S Rees
CLCharlie W Lees
Charlie W Lees
Multiple adalimumab [ADA] biosimilars are now approved for use in inflammatory bowel disease [IBD]; however, effectiveness and safety data remain scarce. We aimed to investigate long-term outcomes of the ADA biosimilar SB5 in IBD patients following a switch from the ADA originator [SB5-switch cohort] or after start of SB5 [SB5-start cohort]. We performed an observational cohort study in a tertiary IBD referral centre. All IBD patients treated with Humira underwent an elective switch to SB5. We identified all these patients in a biological prescription database that prospectively registered all ADA start and stop dates including brand names. Data on IBD phenotype, C-reactive protein [CRP], drug persistence, ADA drug and antibody levels, and faecal calprotectin were collected. In total, 481 patients were treated with SB5, 256 in the SB5-switch cohort (median follow-up: 13.7 months [IQR 8.6–15.2]) and 225 in the SB5-start cohort [median follow-up: 8.3 months [4.2–12.8]). Of the SB5-switch cohort, 70.8% remained on SB5 beyond 1 year; 90/256 discontinued SB5, mainly due to adverse events [46/90] or secondary loss of response [37/90]. In the SB5-start cohort, 81/225 discontinued SB5, resulting in SB5-drug persistence of 60.3% beyond 1 year. No differences in clinical remission [p = 0.53], CRP [p = 0.80], faecal calprotectin [p = 0.40] and ADA trough levels [p = 0.55] were found between baseline, week 26 and week 52 following switch. Injection site pain was the most frequently reported adverse event. Switching from ADA originator to SB5 appeared effective and safe in this study with over 12 months of follow-up.

17 February 2023 in United European Gastroenterology Journal
Verified
Journal Article
Open access
BGBeatriz Gros
Beatriz Gros
NPNikolas Plevris
Nikolas Plevris
NCNathan Constantine‐Cooke
Nathan Constantine‐Cooke
MLMathew Lyons
Mathew Lyons
COClaire O'HAre
Claire O'HAre
LDLauranne A. A. P. Derikx
Lauranne A. A. P. Derikx
Background: Switching from originator infliximab (IFX) to biosimilar IFX is effective and safe. However, data on multiple switching are scarce. The Edinburgh inflammatory bowel disease (IBD) unit has undertaken three switch programmes: (1) Remicade to CT‐P13 (2016), (2) CT‐P13 to SB2 (2020), and (3) SB2 to CT‐P13 (2021).Objective: The primary endpoint of this study was to assess CT‐P13 persistence following switch from SB2. Secondary endpoints included persistence stratified by the number of biosimilar switches (single, double and triple), effectiveness and safety.Methods: We performed a prospective, observational, cohort study. All adult IBD patients on IFX biosimilar SB2 underwent an elective switch to CT‐P13. Patients were reviewed in a virtual biologic clinic with protocol driven collection of clinical disease activity, C‐reactive protein (CRP), faecal calprotectin (FC), IFX trough/antibody levels, and drug survival.Results: 297 patients (CD n = 196 [66%], ulcerative colitis/inflammatory bowel disease unclassified n = 101, [34%]) were switched (followed‐up: 7.5 months [6.8–8.1]). This was the third, second and first IFX switch for 67/297 (22.5%), 138/297 (46.5%) and 92/297 (31%) of the cohort respectively. 90.6% of patients remained on IFX during follow‐up. The number of switches was not independently associated with IFX persistence after adjusting for confounders. Clinical (p = 0.77), biochemical (CRP ≤5 mg/ml; p = 0.75) and faecal biomarker (FC<250 µg/g; p = 0.63) remission were comparable at baseline, week 12 and week 24.Conclusion: Multiple successive switches from IFX originator to biosimilars are effective and safe in patients with IBD, irrespective of the number of IFX switches.